Introduction
============

The fungal genus *Fusarium* is widely distributed as saprobes in the environment but is also able to cause cross-kingdom disease in both plants and mammals ([@B26]; [@B72]). In humans, the disease may manifest in different ways, depending on the portal of entry and the host's immune status. Invasive fusariosis is the most severe manifestation that predominantly affects immunocompromised hosts with hematological malignancies, neutropenia, or glucocorticoid exposure ([@B45], [@B46], [@B48]; [@B21]). In immunocompetent hosts, the fungus may cause onychomycosis ([@B28]), keratitis ([@B69]) or other (sub)cutaneous disorders. The most frequent fungal diseases caused by *Fusarium* species are onychomycosis and keratitis, although other clinical presentations are also observed, such as fungemia, mycetoma, skin infection, lung disease (including allergic disease, hypersensitivity pneumonitis, colonization of a pre-existing cavity, pneumonia in severely immunocompromised patients), and other rare infections (endocarditis, urinary tract infection, osteomyelitis, etc.) ([@B60]; [@B64]; [@B43]; [@B32]).

Species belonging to *Fusarium* are distributed into several species complexes (SC), some of which are important in human and veterinary mycology, particularly *F. solani* SC, *F. oxysporum* SC, *F. fujikuroi* SC, *F. dimerum, F. chlamydosporum, F. incarnatum-equiseti*, and *F. sporotrichoides* ([@B71]; [@B56]; [@B5]; [@B30]). *Fusarium graminearum, F. culmorum, F. fujikuroi* SC, *F. solani* SC, and *F. oxysporum* SC may additionally be found as plant pathogens in maize, wheat, rice, soybean, and tomato crops ([@B10]; [@B19]; [@B35]; [@B38]). Some *Fusarium* species produce mycotoxins during growth in plant tissue, which may contaminate cereal grains and derivatives, making them unsuitable for consumption and causing great agricultural losses ([@B40]; [@B63]).

In attempts to reduce agricultural losses caused by fungal diseases, many strategies have been used, including augmentation of plant resistance, spraying of chemicals, biological control, integrated disease management ([@B61]), and fungicide use, especially azoles ([@B31]). The continuing uncontrolled use of fungicides may lead to selective pressure on environmental fungi ([@B22]). Due to the structural similarity of azoles used in agriculture and medicine, cross-resistance may be observed in clinical fungi ([@B39]; [@B73]). Studies have been performed to test the hypothesis whether fungicide use in agroecosystems may lead to antifungal resistance in *Aspergillus fumigatus* in the clinic ([@B62]; [@B16], [@B15]; [@B39]; [@B8]).

In the medical field, amphotericin B, voriconazole, and posaconazole are the main antifungal drugs recommended for prophylaxis and treatment of human fusariosis ([@B37]; [@B68]; [@B17]; [@B43]; [@B66]; [@B4]). Most *Fusarium* species exhibit high minimal inhibitory concentrations (MICs) to currently used antifungals, especially azoles ([@B33]; [@B24]; [@B7]).

Here we aimed to investigate the susceptibility of *Fusarium* clinical isolates to commonly used antifungals and fungicides and identify the species. For this study, we used strains that were isolated from patients with fusariosis diagnosed in two tertiary Brazilian hospitals in southern Brazil.

Materials and Methods {#s1}
=====================

Strains and Clinical Data
-------------------------

Forty-three clinical *Fusarium* isolates were available from the Laboratory of Mycology at the Federal University of Paraná Hospital, Curitiba, Brazil and Federal University of Rio de Janeiro Hospital, Rio de Janeiro, Brazil, recovered from 40 patients cared between 1985 and 2015. Three patients (32, 36, and 38) had each two isolates recovered, as specified in the [Table 1](#T1){ref-type="table"}. The patient's medical records were reviewed to collect minimal clinical information such as age, gender, treatment, and outcome.

###### 

*Fusarium* isolates data.

  Isolate no.   Species complex   Species                Patient   Type of fusariosis   Underlying disease               Source                  Treatment         GenBank accession no.
  ------------- ----------------- ---------------------- --------- -------------------- -------------------------------- ----------------------- ----------------- -----------------------
  Fu02          FSSC25            *Fusarium* sp.         1         Disseminated         Unknown                          Blood                   VOR               MG738163
  Fu14          FSSC2             *F. keratoplasticum*   2         Disseminated         AML                              Skin                    VOR               MG738189
  Fu27          FSSC2             *F. keratoplasticum*   3         Cutaneous            Arterial insufficiency on legs   Skin                    VOR               MG738193
  Fu34          FSSC5             *F. solani s.s.*       4         Keratitis            None                             Eye                     VOR               MG738195
  Fu37          FSSC2             *F. keratoplasticum*   5         Cutaneous            None                             Skin                    VOR               MG738184
  Fu50          FSSC1             *F. petroliphilum*     6         Disseminated         Myelodysplasia                   Skin                    AMB               MG738167
  Fu51          FSSC1             *F. petroliphilum*     7         Disseminated         AML                              Blood                   FLU               MG738168
  Fu56          FFSC              *F. napiforme*         8         Cutaneous            Fanconi anemia                   Blood                   VOR + AMB         MG738202
  Fu66          FSSC3+4           *F. falciforme*        9         Keratitis            None                             Eye                     VOR               MG738197
  Fu71          FFSC              *F. verticillioides*   10        Disseminated         AML                              Skin                    VOR               MG738201
  Fu72          FSSC7             *N. gamsii*            11        Cutaneous            ALL                              Blood                   VOR               MG738177
  Fu73          FSSC7             *N. gamsii*            12        Disseminated         Non-Hodgkin lymphoma             Skin                    VOR + AMB         MG738178
  Fu75          FSSC1             *F. petroliphilum*     13        Keratitis            None                             Eye                     not done          MG738169
  Fu77          FSSC2             *F. keratoplasticum*   14        Disseminated         Purpura amegakaryocytic          Skin                    not done          MG738190
  Fu78          FFSC              *F. subglutinans*      15        Disseminated         Aplastic anemia                  Blood                   VOR + AMB         MG738203
  Fu80          FSSC7             *N. gamsii*            16        Unknown              Unknown                          Skin                    Unknown           MG738179
  Fu86          FSSC25            *Fusarium* sp.         17        Unknown              Unknown                          Skin                    Unknown           MG738164
  Fu87          FSSC              *Fusarium* sp.         18        Cutaneous            ALL                              Blood                   VOR               MG738166
  Fu89          FSSC35            *Fusarium* sp.         19        Disseminated         Unknown                          Blood                   VOR               MG738162
  Fu92          FSSC1             *F. petroliphilum*     20        Cutaneous            Aplastic anemia                  Skin                    VOR + AMB         MG738170
  Fu93          FSSC20            *N. suttoniana*        21        Disseminated         CML                              Skin                    VOR + AMB         MG738198
  Fu94          FSSC              *F. xanthoxyli*        22        Disseminated         Unknown                          Skin                    VOR               MG738182
  Fu96          FSSC2             *F. keratoplasticum*   23        Disseminated         ALL                              Skin                    VOR               MG738185
  Fu97          FSSC2             *F. keratoplasticum*   24        Disseminated         ALL                              Endotracheal aspirate   VOR + AMB         MG738194
  Fu99          FSSC1             *F. petroliphilum*     25        Cutaneous            Aplastic anemia                  Skin                    VOR + ISA         MG738171
  Fu100         FSSC20            *N. suttoniana*        26        Keratitis            None                             Eye                     VOR               MG738199
  Fu101         FSSC2             *F. keratoplasticum*   27        Disseminated         Myocardium revascularization     Skin                    VOR               MG738183
  Fu103         FSSC20            *N. suttoniana*        28        Keratitis            None                             Eye                     VOR               MG738200
  Fu105         FSSC2             *F. keratoplasticum*   29        Disseminated         Myelodysplasia                   Skin                    VOR               MG738191
  Fudm2         FSSC7             *N. gamsii*            30        Disseminated         ALL                              Blood                   VOR + AMB         MG738180
  FuB302.1      FSSC2             *F. keratoplasticum*   31        Unknown              Rheumatoid arthritis             Skin                    VOR               MG738192
  FuB371        FSSC5             *F. solani s.s.*       32        Unknown              ALL                              Skin                    VOR               MG738196
  FuB391        FSSC33            *F. pseudensiforme*    33        Unknown              Unknown                          Skin                    Unknown           MG738161
  FuB478        FSSC2             *F. keratoplasticum*   34        Unknown              AML                              Skin                    AMB               MG738186
  FuB560        FSSC7             *N. gamsii*            35        Unknown              CML                              Skin                    VOR + lipid AMB   MG738181
  FuB604        FSSC1             *F. petroliphilum*     36        Unknown              ALL                              Synovial fluid          VOR               MG738172
  FuB665        FSSC1             *F. petroliphilum*     36        Unknown              ALL                              Synovial fluid          VOR               MG738173
  FuB817        FSSC1             *F. petroliphilum*     37        Unknown              Myelodysplasia                   Skin                    VOR               MG738174
  FuB920        FSSC1             *F. petroliphilum*     32        Unknown              ALL                              Synovial fluid          VOR               MG738175
  FuB935        FSSC2             *F. keratoplasticum*   38        Unknown              AML                              Skin                    VOR + lipid AMB   MG738187
  FuB936        FSSC2             *F. keratoplasticum*   38        Unknown              AML                              Skin                    VOR + lipid AMB   MG738188
  FuH79A        FSSC18            *Fusarium* sp.         39        Unknown              AML                              Blood                   VOR + lipid AMB   MG738165
  FuH05         FSSC1             *F. petroliphilum*     40        Unknown              Unknown                          Blood                   Unknown           MG738176
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; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; AMB, amphotericin B; FLU, fluconazole; ISA, isavuconazole; VOR, voriconazole; Unknown, no data available.

DNA Isolation, PCR, and Sequencing
----------------------------------

*Fusarium* isolates were cultured on Sabouraud dextrose agar plus chloramphenicol (SDA; Difco Laboratories, Detroit, MI, United States). Culture plates were incubated at 26 and 37°C and observed daily for growth up to 7 days. Initial identification of *Fusarium* isolates was based on macroscopic colony morphology and microscopic features in a lacto-phenol wet mount preparation according to standard laboratory procedures. Final identification was done using molecular methods. DNA extraction was performed as described by [@B34]. Conidia were suspended in 400 μL bacterial lysis buffer (Roche Diagnostics, Almere, Netherlands) followed by mechanical lysis in a MagNA Lyser (Roche Diagnostics) for 30 s at 4,500 × *g*. Cells were inactivated for 10 min by heating at 100°C and 200 μL of the solution was used for automated DNA extraction by using the MagNA Pure 96 platform (Roche Diagnostics) with a final elution volume of 100 μL.

Fragments of the translation elongation factor 1-alpha (*TEF1*α) gene were amplified and sequenced using PCR protocols following the methods published by [@B2] with primers EF1 (5′-ATGGGTAAGGA(A/G)GACAAGAC-3′) and EF2 (5′-GGA(G/A)GTACCAGT(G/C)ATCATGTT-3′) ([@B50]). Sequencing reaction mixtures contained 1 ng/μL of template DNA, 1 pmol/μL, 0.7 μL of BigDye^TM^ terminator (Applied Biosystems, Foster City, CA, United States), 3 μL buffer and ultra-pure water to 10 μL final volume. Sequencing PCR was performed as follows: 95°C for 1 min, followed by 30 cycles consisting of 95°C for 10 s, 50°C for 5 s and 60°C for 2 min. Sequencing was done on an ABI 3730xL automatic sequencer (Applied Biosystems).

Alignment and Phylogenetic Analyses
-----------------------------------

For preliminary identification, a homology search for the sequences of *TEF1*α was done using the BLAST tool in NCBI database, the CBS database, FUSARIUM-ID ([@B27]) and the *Fusarium* MLST ([@B52]) database down to species and haplotype level. DNA sequences were edited, and consensus sequences were assembled by the SeqMan package of Lasergene software (DNAStar, Madison, WI, United States). Retrieved alignments were manually corrected to avoid mis-paired bases. Sequences were exported as FASTA files. Sequences of *TEF1*α were aligned with MAFFT program^[1](#fn01){ref-type="fn"}^ and adjusted in MEGA6 ([@B67]). The best-fit model of evolution was determined by MEGA6. Maximum likelihood (ML) analysis was done with RAxML-VI-HPC v. 7.0.3 with non-parametric bootstrapping using 1000 replicates. GenBank accession numbers are shown in [Table 1](#T1){ref-type="table"}.

Antifungal Susceptibility Testing
---------------------------------

Antifungal susceptibility testing by the broth microdilution method was performed according to the CLSI protocol M38-A2 ([@B18]). Antifungal agents tested were amphotericin B (Bristol Myers Squibb, Woerden, Netherlands), itraconazole (Janssen Pharmaceutica, Beerse, Belgium), voriconazole (Pfizer, Sandwich, United Kingdom), posaconazole (Merck, NJ, United States) and isavuconazole (Basilea Pharmaceutica, Basel, Switzerland). The fungicides used were difenoconazole, tebuconazole and propiconazole (all from Sigma-Aldrich, St. Louis, MO, United States). The concentrations of antifungals ranged from 0.031 to 32 μg mL^-1^. *Fusarium* isolates were cultured onto Sabouraud glucose agar until sporulation at 30°C and the inocula were adjusted to 1.8--3 × 10^6^ CFU/mL in saline supplemented with 0.05% Tween 20 to perform the test. Microdilution plates were incubated at 35°C for 48 h and the MICs were defined as the lowest concentration able to complete growth inhibition when compared with the drug free growth control. *Aspergillus flavus* ATCC 204304, *Candida parapsilosis* ATCC 22019 and *C. krusei* ATCC 6258 reference strains were used as quality controls ([@B18]). Interpretation of the MIC values was based on Epidemiological Cutoff Values (ECV) according to previous literature data ([@B23]). MIC~50~ and MIC~90~ were obtained by ordering the data for each antifungal in ascending order and selecting the median and 90th quantile, respectively. Geometric mean MICs were calculated using Microsoft Office Excel 2010 software (Microsoft, Redmond, WA, United States). When the MIC was more or less than dilutions tested, 1 log~2~ dilution higher or 1 log~2~ dilution lower was considered for calculating the geometric mean.

Results
=======

Clinical Data
-------------

The median age of the 40 patients was 36 years (range 2--78 years) and 21 were female. Disseminated fusariosis was the most frequent clinical form (*n* = 16, 37.2%), followed by cutaneous infections (*n* = 7; 16.3%) and keratitis (*n* = 5; 11.6%). *Fusarium* strains were isolated most frequently from the skin (*n* = 24; 55.8%), blood (*n* = 10; 23.2%), and eye (*n* = 5; 11.6%). Acute lymphoblastic leukemia (*n* = 7; 16.3%) and acute myeloid leukemia (*n* = 6; 13.9%) were the most commonly underlying conditions. Twelve out of 16 cases of disseminated fusariosis occurred in patients with hematological malignancies. Voriconazole monotherapy was the treatment in 21 (48.8%) patients, 13 of which (61.9%) had a favorable response to therapy. Combination therapy with voriconazole and deoxycholate amphotericin B was given to 7 (16.3%) patients, and voriconazole plus liposomal amphotericin B in 3 patients (7%). Other therapies were deoxycholate amphotericin B alone (*n* = 2; 4.7%), fluconazole alone (*n* = 1; 2.3%), and voriconazole associated with itraconazole (*n* = 1; 2.3%). For 2 (4.7%) patients no therapy was given. Information about treatment was not available in 6 cases. The isolates and respective patients' clinical data are shown in [Table 1](#T1){ref-type="table"}.

Molecular Identification and Phylogeny
--------------------------------------

Phylogenetic analysis based on *TEF1*α sequences was conducted in order to position the isolates in the *Fusarium solani* complex and their respective species complexes ([Figure 1](#F1){ref-type="fig"}). The analysis included 55 sequences from different species, and one outgroup taxa (NRRL 22316 *F. staphyleae*). Within FSSC, *F. keratoplasticum* FSSC 2 (*n* = 12) was most often involved in cases of fusariosis, followed by *F. petroliphilum* FSSC 1 (*n* = 10), *Neocosmospora gamsii* FSSC 7 (*n* = 5), *N. suttoniana* FSSC 20 (*n* = 3), *F. solani sensu stricto* FSSC 5 (*n* = 2), *Fusarium* sp. FSSC 25 (*n* = 2), *Fusarium* sp. FSSC 35 (*n* = 1), *Fusarium* sp. FSSC 18 (*n* = 1), *F. falciforme* FSSC 3+4 (*n* = 1), *F. pseudensiforme* (*n* = 1), and *F. solani* f. *xanthoxyli* (*n* = 1). One isolate clustered in a separate clade (unknown species/haplotype) forming a distinct, well-supported, unnamed lineage and which matched only with a single strain from Colombia (LEMM 110739, GenBank accession no. LN827969, misidentified as *Fusarium solani*). We also identified the following members of the *Fusarium fujikuroi* species complex (FFSC): *F. subglutinans* (*n* = 1), *F. verticillioides* (*n* = 1), and *F. napiforme* (*n* = 1) which are not included in the phylogenetic analysis.

![Maximum likelihood (ML) phylogenetic tree created from TEF1 sequences of 55 *Fusarium* sequences. Total alignment length is 707 bp. Thousand bootstrap-replications. The tree was rooted with NRRL 22316 *F. staphyleae*.](fmicb-10-00737-g001){#F1}

Antifungal Susceptibility Profiles
----------------------------------

MICs are shown in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. Amphotericin B had relatively high activity with MICs ranging from 0.5 to 32 μg mL^-1^, except for the isolates Fu73 (novel lineage) and Fu80 (*Neocosmospora gamsii* FSSC7), which showed MIC values of 8 and 32 μg mL^-1^, respectively. All isolates exhibited high MICs to itraconazole with MICs \>32 μg mL^-1^. The FSSC had MIC values of posaconazole and difenoconazole higher than 32 μg mL^-1^. Other azoles showed to be less effective against FSSC isolates with high MIC values of 8--\>32 μg mL^-1^. *Fusarium keratoplasticum* showed high MIC values (8--\>32 μg mL^-1^) for itraconazole, voriconazole, posaconazole and isavuconazole. In counterpart, azoles showed activity against FFSC with MIC values ranges of 1--8 μg mL^-1^ and with only one isolate of *F. napiforme* showing MIC of \>32 μg mL^-1^ for posaconazole.

###### 

Minimal inhibitory concentrations of *Fusarium* clinical isolates.

  Species complex   Antifungal           No. of isolates per MIC value (μg mL^-1^)                                                    
  ----------------- -------------------- ------------------------------------------- -- -- -- ---- -------- --- --- -------- --- ---- --------
  FSSC (*n* = 40)   **Amphotericin B**                                                        10   **16**   9   4                1    
                    **Itraconazole**                                                                                                  **40**
                    **Voriconazole**                                                                        1   2   **21**   7   3    6
                    **Posaconazole**                                                                                                  **40**
                    **Isavuconazole**                                                                                            10   **30**
                    **Difenoconazole**                                                                                                **40**
                    **Tebuconazole**                                                                                         3   4    **33**
                    **Propiconazole**                                                                                        1        **39**
  FFSC (*n* = 3)    **Amphotericin B**                                                             1        2                         
                    **Itraconazole**                                                                                                  3
                    **Voriconazole**                                                                        2   1                     
                    **Posaconazole**                                                          1    1                                  1
                    **Isavuconazole**                                                                           3                     
                    **Difenoconazole**                                                                          1   2                 
                    **Tebuconazole**                                                                        1   2                     
                    **Propiconazole**                                                                       1       2                 
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species complex; MIC, minimum inhibitory concentration. The modes are depicted in bold.

###### 

Individual minimal inhibitory concentration (μg mL^-1^) of all *Fusarium* spp. and *Neocosmospora* spp. isolates.

  Isolate    Identification -- EF                 Minimal inhibitory concentration (μg mL^-1^)                                                               
  ---------- ------------------------------------ ---------------------------------------------- --------- --------- --------- --------- --------- --------- ---------
                                                  **AMB**                                        **ITC**   **VOR**   **POS**   **ISA**   **DIF**   **TEB**   **PRO**
                                                                                                                                                             
  Fu101      *F. keratoplasticum* (FSSC 2)        4                                              64        16        64        64        64        64        64
  Fu77       *F. keratoplasticum* (FSSC 2)        2                                              64        16        64        64        64        64        64
  Fu14       *F. keratoplasticum* (FSSC 2)        0.5                                            64        64        64        64        64        64        64
  Fu105      *F. keratoplasticum* (FSSC 2)        2                                              64        8         64        64        64        64        64
  FuB302.1   *F. keratoplasticum* (FSSC 2)        2                                              64        16        64        64        64        64        64
  Fu97       *F. keratoplasticum* (FSSC 2)        1                                              64        16        64        64        64        64        64
  Fu27       *F. keratoplasticum* (FSSC 2)        4                                              64        64        64        64        64        64        64
  FuB936     *F. keratoplasticum* (FSSC 2)        1                                              64        8         64        64        64        64        64
  Fu96       *F. keratoplasticum* (FSSC 2)        1                                              64        8         64        32        64        16        64
  FuB935     *F. keratoplasticum* (FSSC 2)        2                                              64        8         64        64        64        64        64
  Fu37       *F. keratoplasticum* (FSSC 2)        1                                              64        32        64        64        64        64        64
  FuB478     *F. keratoplasticum* (FSSC 2)        2                                              64        8         64        64        64        64        64
             Range^∗^                             0.5--4                                         64        8--64     64        32--64    64        16--64    64
             MIC~50~^∗^                           2                                              64        16        64        64        64        64        64
             MIC~90~^∗^                           4                                              64        64        64        64        64        64        64
             Geometric mean^∗^                    1.58                                           64        16        64        60.4      64        57.01     64
  FuB920     *F. petroliphilum* (FSSC 1)          1                                              64        8         64        64        64        64        64
  Fu92       *F. petroliphilum* (FSSC 1)          1                                              64        8         64        32        64        64        64
  Fu50       *F. petroliphilum* (FSSC 1)          2                                              64        4         64        32        64        64        64
  Fu51       *F. petroliphilum* (FSSC 1)          0.5                                            64        16        64        64        64        64        64
  Fu99       *F. petroliphilum* (FSSC 1)          1                                              64        8         64        32        64        32        64
  Fu75       *F. petroliphilum* (FSSC 1)          0.5                                            64        8         64        64        64        64        64
  FuB665     *F. petroliphilum* (FSSC 1)          1                                              64        8         64        64        64        64        64
  FuB817     *F. petroliphilum* (FSSC 1)          0.5                                            64        8         64        32        64        64        64
  FuB604     *F. petroliphilum* (FSSC 1)          1                                              64        8         64        32        64        64        64
  FuH05      *F. petroliphilum* (FSSC 1)          0.5                                            64        8         64        64        64        64        64
             Range^∗^                             0.5--2                                         64        4--16     64        32--64    64        32--64    64
             MIC~50~^∗^                           1                                              64        8         64        32        64        64        64
             MIC~90~^∗^                           1                                              64        8         64        64        64        64        64
             Geometric mean^∗^                    0.81                                           64        8         64        45.25     64        59.71     64
  Fu72       *N. gamsii* (FSSC 7)                 1                                              64        64        64        64        64        64        64
  FuB560     *N. gamsii* (FSSC 7)                 2                                              64        8         64        32        64        32        64
  Fudm02     *N. gamsii* (FSSC 7)                 4                                              64        8         64        64        64        64        64
  Fu80       *N. gamsii* (FSSC 7)                 32                                             64        8         64        64        64        64        64
  Fu73       *N. gamsii* (FSSC 7)                 4                                              64        8         64        64        64        64        64
  Fu93       *N. suttoniana* (FSSC 20)            1                                              64        64        64        64        64        64        64
  Fu100      *N. suttoniana* (FSSC 20)            0.5                                            64        64        64        64        64        64        64
  Fu103      *N. suttoniana* (FSSC 20)            1                                              64        32        64        64        64        64        64
  Fu02       *Fusarium* sp. (FSSC 25)             0.5                                            64        32        64        64        64        32        64
  Fu86       *Fusarium* sp. (FSSC 25)             1                                              64        8         64        64        64        64        64
  FuB371     *F. solani sensu stricto* (FSSC 5)   2                                              64        8         64        64        64        64        64
  Fu34       *F. solani sensu stricto* (FSSC 5)   0.5                                            64        16        64        64        64        64        64
  FuH79A     *Fusarium* sp. (FSSC 18)             2                                              64        8         64        64        64        32        64
  Fu89       *Fusarium* sp. (FSSC 35)             0.5                                            64        16        64        64        64        64        64
  Fu87       *Fusarium* sp.                       1                                              64        4         64        32        64        64        64
  Fu66       *F. falciforme* (FSSC 3+4)           0.5                                            64        2         64        32        64        16        16
  Fu94       *F. solani* f. *xanthoxyli*          1                                              64        64        64        64        64        64        64
  FuB391     *F. pseudensiforme*                  1                                              64        8         64        32        64        16        64
  Fu78       *F. subglutinans*                    1                                              64        2         0.5       4         8         4         2
  Fu71       *F. verticillioides*                 2                                              64        4         1         4         8         4         8
  Fu56       *F. napiforme*                       2                                              64        2         64        4         4         2         8
                                                                                                                                                             

FSSC,

Fusarium solani

species complex; FFSC,

Fusarium fujikuroi

species complex; AMB, amphotericin B; ITC, itraconazole; VOR, voriconazole; POS, posaconazole; ISA, isavuconazole; DIF, difenoconazole; TEB, tebuconazole; PRO, propiconazole.

∗

Values calculated for species with sufficient number of isolates.

Among the agricultural fungicides, difenoconazole had the lowest activity against FSSC with MICs of \>32 μg mL^-1^ for all isolates, followed by propiconazole and tebuconazole. In contrast, the three fungicides showed activity against FFSC, with MIC ranges of 2--8 μg mL^-1^.

Discussion
==========

Invasive fusariosis is a severe disease that affects immunocompromised patients, mostly those with underlying hematological malignancies ([@B45], [@B49]; [@B44]; [@B12]; [@B13]). In agreement with the literature, the present study found the majority of disseminated cases of fusariosis (11/16) occurring in patients with acute lymphoblastic leukemia and acute myeloid leukemia. Disseminated fusariosis in these patients has a poor prognosis and mortality rates are close to 75% ([@B44]; [@B12]). The treatment of this infection is a challenge and in the absence of better alternatives, voriconazole and amphotericin B are the most recommended therapies ([@B44]; [@B47]; [@B68]; [@B9]).

Results from our sequence analysis show that twelve phylogenetic species within the *solani* complex were involved in 40 cases and responsible for 93% of the fusariosis in this study. In addition, three species were identified as belonging to the *fujikuroi* complex (7%). Of the 12 species and haplotypes of FSSC where the 40 strains were distributed, six belonged to previously described *Fusarium* species or varieties (*F. keratoplasticum, F. falciforme, F. petroliphilum, Fusarium solani sensu stricto, F. ambrosium*, and *F. solani* f. *xanthoxyli*), three to known haplotypes (FSSC 25, FSSC 35, FSSC 18, respectively), while two clades were recently described in *Neocosmospora* \[FSSC 7 = *N. gamsii*, FSSC 20 = *N. suttoniana* ([Figure 1](#F1){ref-type="fig"})\]; note that according to these authors ([@B57]) the entire *Fusarium solani* species complex phylogenetically constitutes a separate genus, *Neocosmospora*, but not all extant species have consistently been denominated, resulting in the use of two generic names for closely related species. One strain (Fu87) was identified as a novel phylogenetic lineage within FSSC and matched with LEMM 110739, which was previously reported by [@B28] from an onychomycosis case. Numerous haplotypes and the newly reported lineage have remained yet unnamed. In the present study, *F. keratoplasticum* (FSSC 2) was the most often recorded species (28%), followed by *F. petroliphilum* (FSSC 1, 23.3%), which agrees with data of [@B51]. In accordance with literature data ([@B51]; [@B74]) we also encountered *Fusarium solani sensu stricto* (FSSC 5) causing keratitis.

Members of FSSC with a significant role in clinical infections in our data set comprised *F. falciforme* (FSSC 3+4), *F. keratoplasticum* (FSSC 2), *F. lichenicola* (FSSC 16), *F. metavorans* (FSSC 6), *F. petroliphilum* (FSSC 1), *F. pseudensiforme* (FSSC 33), and *F. solani sensu stricto* (FSSC 5) ([@B3]; [@B11]). Another lineage associated with opportunistic infections in FSSC that has been named is FSSC 27 (*Phialophora cyanescens* = *Cylindrocarpon cyanescens*), which was recently recombined as *Neocosmospora cyanescens*, MB 813864 ([@B65]). This species of FSSC lacks a name in *Fusarium*, while conversely *F. solani* f. *xanthoxyli* has no name in *Neocosmospora*; thus, consistent naming of the fungi in FSSC is impossible. Recently, a study from Japan also reported that haplotypes FSSC 9 and FSSC 18 are associated with opportunistic infections and with mycotic keratitis ([@B41]), while a German report found FSSC 9 and FSSC 25 to be involved in endophthalmitis ([@B74]). Literature data indicate that species within FSSC are the main cause of fusariosis worldwide ([@B58]; [@B30]; [@B69]). *Fusarium keratoplasticum* has been reported as the etiologic cause of disseminated fusariosis in hematologic patients ([@B25]; [@B14]), as well as keratitis ([@B69]), onychomycoses ([@B28]; [@B29]) and eumycetoma ([@B9]). In addition, *F. keratoplasticum* is an important veterinary etiologic agent, causing disease in equine and marine vertebrates as well as in invertebrates ([@B53]).

In the present study, we identified additional species and haplotypes for the first time from clinical samples, including *F. pseudensiforme* (FSSC 33), *F. solani* f. *xanthoxyli* (FSSC 22), *N. gamsii* (haplotype 7 -- FSSC 7), *N. suttoniana* (haplotype 20 -- FSSC 20), *Fusarium* sp. (FSSC 25), and *Fusarium* sp. (FSSC 35) ([Figure 1](#F1){ref-type="fig"}), but confirmed case reports are as yet lacking. All these haplotypes are phylogenetically distinct from described species but remain unnamed as molecular siblings. Our data suggest that these additional species/haplotypes might be of importance for human health, although on the other hand it remains questionable whether formal description of the FSSC lineages as formal species is meaningful. Using *TEF1*α sequences strain Fu87 matched with an undescribed lineage (LEMM 110739) previously reported by [@B28] from clinical samples in Colombia.

The number of reports of *Fusarium* species that were previously considered to be exclusive plant pathogens but are now implicated in superficial and systemic infections in humans and animals is obviously increasing ([@B75]). *Fusarium* is rather unique in having pathogenic strategies to infect plants as well as animals including humans. This trans-kingdom pathogenicity has been demonstrated for the molecular siblings *F. falciforme, F. keratoplasticum* and *F. solani sensu stricto* within FSSC ([@B42]; [@B59]). Thus, our findings support the concept that *Fusarium* might serve as good model for studying the genetic basis of trans-kingdom pathogenicity in fungi ([@B54]).

Our findings agree with reports from different regions in the world where the most frequently identified species causing human infections belonged to the FSSC followed by the *fujikuroi* and *oxysporum* species complexes ([@B7], [@B6]; [@B66]). In Brazil species of FSSC were the most commonly reported, followed by the *fujikuroi* species complex ([@B58]) and *oxysporum* species complex ([@B20]). Future studies including larger numbers of isolates are warranted to establish the prevalence of rare *Fusarium* species in clinical settings. In our study, *F. keratoplasticum* showed high MIC values (8--\>32 μg mL^-1^) for most azoles tested and agricultural fungicides, with geometric mean MICs of 1.58 μg mL^-1^ for amphotericin B, 16 μg mL^-1^ for voriconazole and 64 μg mL^-1^ for posaconazole, the most effective drugs against *Fusarium* species ([@B36]). [@B55] observed that *F. keratoplasticum* was the species most frequently found in onychomycoses lesions and was more susceptible to amphotericin B and voriconazole than the other antifungals tested, with geometric mean MICs of 4.88 and 20.09 μg mL^-1^, respectively, higher than those observed in the present study. A study performed with 89 *Fusarium* isolates obtained from patients with superficial infections revealed that 49 (55.1%) of isolates belonged to *F. solani* species complex and 40 belonged to *F. oxysporum* species complex. Most of isolates showed high MIC values to antifungals tested, with modal MIC values of \>16 μg mL^-1^ to amphotericin B, itraconazole, voriconazole, and posaconazole ([@B28]). Itraconazole had no *in vitro* effect against the isolates tested, which agrees with [@B70]. Similarly, [@B29] observed high MIC values of flucytosine, itraconazole, posaconazole, anidulafungin, and caspofungin for clinical isolates of *F. keratoplasticum*.

In view of the resistance of *Fusarium* spp. to several antifungal agents, some studies have tested its susceptibility to new antifungals. [@B1] tested luliconazole, lanoconazole, and efinaconazole against clinical and environmental *Fusarium* isolates members of the *F. fujikuroi* species complex (*n* = 94), *F. solani* species complex (*n* = 14), *F. oxysporum* species complex (*n* = 11), *F. lateritium* species complex (*n* = 1), and *F. graminearum* species complex (*n* = 1). Overall, *Fusarium* species demonstrated lower MICs to luliconazole, lanoconazole and efinaconazole (geometric mean MICs of 0.005, 0.013, and 0.85 μg mL^-1^, respectively) when compared with voriconazole and amphotericin B (geometric mean MICs of 1.37 and 1.9 μg mL^-1^, respectively). In addition, [@B70] tested the susceptibility of *F. solani* species complex (*n* = 18), *F. dimerum* species complex (*n* = 2), and *F. incarnatum-equiseti* species complex (*n* = 1) to efinaconazole. The concentrations of efinaconazole necessary to inhibited fungal growth vary from 0.031 to 2 μg mL^-1^, with geometric mean MICs varying from 0.08 to 0.7 μg mL^-1^ depending on *Fusarium* species. These data suggested that luliconazole, lanoconazole and efinaconazole are effective drugs that may be used against fusariosis.

Conclusion
==========

In conclusion, *F. keratoplasticum* and *F. petroliphilum* were the most frequent species in this study. Amphotericin B showed lower MICs against *Fusarium* species whereas the antifungal azoles and the fungicide difenoconazole exhibited higher MICs against FSSC.
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